Background {#Sec1}
==========

Myeloid sarcoma (MS) represents a rare malignancy that encompasses immature or mature myeloid blasts occurring at any extra-medullary site with normal architectural effacement. It was first described by Burns \[[@CR1]\] in 1811 and termed as chloroma by King \[[@CR2]\] in 1853 because a subset of MS contains abundant myeloperoxidase (MPO) and turns green upon exposure to oxygen \[[@CR3], [@CR4]\]. Dock identified the association of MS with acute leukemia in 1893 \[[@CR5]\], and Rappaport referred it as "granulocytic sarcoma" in 1996 for the neoplasm comprises of immature granulocytic cells and resembles a sarcoma \[[@CR6]\]. Although other historical names have been used, MS was recommended by world health organization in 2001. MS might be isolated \[[@CR7], [@CR8]\], precede \[[@CR9]\], coincide with the onset \[[@CR10]\] and relapse \[[@CR11]\] of AML, as well as correlated with myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) \[[@CR12]\]. The incidence of MS is between 1.1 and 9.1% in patients with AML, MDS or MPN \[[@CR11], [@CR13]\]. MS occurs in nearly any sites, and the most common sites include lymphoid tissues, central nervous system, lung, kidney and gastrointestinal tract \[[@CR14]\]. Female genital system is a much rarer location that less than a hundred cases have been reported in English-written literature \[[@CR8], [@CR10], [@CR11]\]. The frequency of gynecological involvement from high to low was the ovary, cervix, uterus and vulva \[[@CR10], [@CR15]\]. Precisely, only 8 MS patients involving the vulva were identified in literature \[[@CR16]\]. Here, we report an unusual case of vulvar MS as the initial presentation of AML, and review the literature of Chinese patients with gynecological MS.

Case presentation {#Sec2}
=================

A 47-year-old woman presented with fever and chronic ulceration on her vulva for one and a half month in January 2017. The patient had no significant past medical or family history. She had been given levofloxacin and topical douche in another hospital, but the vulvar lesions continued to aggravate. Gynecological evaluation revealed two large well-demarcated ulcers on bilateral labia majora (Fig. [1](#Fig1){ref-type="fig"}) without involvement of labia minora and vagina. The patient underwent an incisional biopsy and the cut surface of specimen was grey-white. Microscopically, the dermis was infiltrated with diffuse noncohesive sheets of medium-sized myeloid precursor cells that have large vesicular nuclei, prominent nucleoli, and scarce ill-defined cytoplasm with mild pleomorphism (Fig. [2](#Fig2){ref-type="fig"}a). Abundant neutrophils and sparse plasma cells were observed. Immunohistochemistry (IHC) demonstrated positive reactions with MPO (Fig. [2](#Fig2){ref-type="fig"}b), lysozyme (Fig. [2](#Fig2){ref-type="fig"}c), CD43 (Fig. [2](#Fig2){ref-type="fig"}d), CD68 (Fig. [2](#Fig2){ref-type="fig"}e), CD38 and CD117, and negative reactions with T-cell markers (CD3, CD5, CD56), B-cell markers (CD20, Bcl-2, Bcl-6) and plasma-cell makers (CD138). Ki-67 was expressed in 80% of the neoplastic cells (Fig. [2](#Fig2){ref-type="fig"}f). Therefore, she was diagnosed as MS and admitted to hospital. Fig. 1Two large well-demarcated ulcers on bilateral labia majora Fig. 2Hematoxylin-eosin and immunohistochemical staining of vulvar ulcers. Diffuse noncohesive sheets of medium-sized myeloid precursor cells in the dermis (**a**); Immunohistochemical staining result is positive for myeloperoxidase (**b**), lysozyme (**c**), CD43 (**d**), CD68 (**e**) and ki-67 (**f**)

On admission, her peripheral blood count showed white blood cells 6.78 × 10^9^/L, hemoglobin 80 g/L, hematocrit 26%, platelets 6.78 × 10^9^/L. Differential blood count was as follows: blasts 71%, unclassifiable cells 16%, neutrophils 24%, lymphocytes 58%, monocytes 2%. Her peripheral blood smear revealed the percentage of leukemic cells was 28%, while the bone marrow (BM) aspirate contained 44.5% leukemic cells. Flowcytometric analysis showed myeloblast count of 74%, which expressed CD13, CD33, CD117 and HLA-DR. Cytogenetic study of the BM discovered a normal 46, XX karyotype. Fluorescence in situ hybridation (FISH) analysis did not detect any common fusion genes in hematologic diseases such as AML, MDS, eosinophilia and acute lymphoblastic leukemia (ALL). Given the results, a diagnosis of AML (M2 type, FAB classification) was made and MS of the vulva was the earliest symptom in this patient.

She subsequently received induction chemotherapy with idarubicin (10 mg/m^2^ for 3 days) and cytarabine (100 mg/m^2^ for 7 days) that achieved complete remission 1 month later with the ratio of minimal residual disease being 0.017%. Meanwhile, the vulvar ulceration healed without other therapy (Fig. [3](#Fig3){ref-type="fig"}). In this period, the patient developed upper gastrointestinal bleeding and acute inferior myocardial infarction that recovered after conservative treatment. She then received 5 cycles of intensification therapy (high-dose cytarabine 3 g/m^2^/12 h for 3 days) along with intrathecal injection of methotrexate and cytarabine for 4 times. Neither a family nor unrelated donor for haematopoietic stem cell transplantation (HSCT) had been found. Currently, she remained in complete remission 27 months from the time of diagnosis on follow up. Fig. 3Vulvar ulceration healed after chemotherapy

Discussion and conclusions {#Sec3}
==========================

We searched following terms of "genitals and MS" and "genitals and AML" in the PubMed and Chinese literature databases including Wanfang Data (<http://www.wanfangdata.com.cn/index.html>), VIP Journals (<http://qikan.cqvip.com/>) and China Knowledge Resource Integrated Database (<http://www.cnki.net/>). In total, we identified 54 MS cases involving gynecologic tract reported between 1999 and 2018, details of which are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Reviews of Chinese cases of gynecological myeloid sarcomaNoAuthorAgeTime of genital involvementNon-systemic involvementSystemic involvementAML TypeTreatmentOutcomeVulva1Huang et al. \[[@CR17]\]78InitialNoneSimultaneouslyNARefusedNot stated2Yang et al. \[[@CR18]\]27InitialNoneSimultaneouslyM2CT (DNR + ARA-C)CR, ANEL 36 mo3He et al. \[[@CR19]\]25InitialPelvic LASimultaneouslyM5RefusedNot stated4Hu et al. \[[@CR20]\]45Relapse (MDS)PerirenalAfter 1.4 mo of vulvar MSM5CT (ARA-C + IDA)CR, died 3 mo (sepsis)5Fang et al. \[[@CR21]\]75IsolatedPulmonary SCCNoneNACT (HHT + ARA-C) → RTMS resolved, relapse 10 mo later6Our case47InitialNoneSimultaneouslyM2CT (ARA-C + IDA, ARA-C)II (ARA-C + MTX)CR, ANEL 27 moVagina7Li et al. \[[@CR22]\]55IsolatedNoneNoneNASG → RefusedDied 10 mo8Xue et al. \[[@CR23]\]61Not statedRegional LANot statedM2Not statedNot statedUterine cervix9Lu et al. \[[@CR24]\]41InitialNoneAfter 19 d of SGM2SG → CTDied 27d (cerebral hemorrhage)10Qu et al. \[[@CR25]\]28InitialNoneSimultaneouslyM2bNot statedNot stated11Zhang et al. \[[@CR26]\]45InitialNoneSimultaneouslyNot statedCT (DNR + ARA-C)Not stated12Wen et al. \[[@CR27]\]49Not statedNot statedNot statedNARTDied 2 mo13Feng et al. \[[@CR28]\]40IsolatedNoneNoneNASGNot stated14Gao et al. \[[@CR29]\]34IsolatedNoneNoneNACT (ARA-C + DNR) → SG → CT (ARA-C + DNR)ANEL15Li et al. \[[@CR30]\]34IsolatedNoneNoneNACT (DNR + ARA-C) → SGANEL16Zheng et al. \[[@CR31]\]43IsolatedNoneNoneNACT (HHT + ARA-C)ANEL 20 mo17Li et al. \[[@CR22]\]46IsolatedNoneNoneNASG → CT (DNR + ARA-C)ANEL 8 mo18Gu et al. \[[@CR32]\]42IsolatedNoneNoneNACT (DNR + ARA-C)ANEL 3 mo19Yu et al. \[[@CR33]\]28IsolatedNoneNoneNACT (IDA + ARA-C)Died 18 mo20Liu et al. \[[@CR34]\]27IsolatedNoneNoneNASGANEL 15 mo21Zhang et al. \[[@CR35]\]23Relapse (AML)NoneAfter 1 mo of MSM2CT (ARA-C + MIT)CR22Liu et al. \[[@CR36]\]46Secondarysupramaxilla, breastAfter 18 mo of MSNot statedCT (DNR + ARA-C, HHT + ARA-C, MIT + ARA-C) → pelvic RTDied 4 mo after cessation of CT23Zhu et al. \[[@CR37]\]63Not statedNot statedNoneNACT → RTCR24Zhu et al. \[[@CR37]\]45Not statedNot statedNoneNACT → SGDied25Xue et al. \[[@CR23]\]46Not statedHead, neck, regional LANot statedNANot statedNot stated26Zuo et al. \[[@CR38]\]42InitialNoneAML during CTNot statedSG → CT (DNR + ARA-C)Died 12 mo27Zuo et al. \[[@CR38]\]51IsolatedNoneNoneNACT → SG → CT (DNR + ARA-C) → gingiva 55 mo later → CT + RT + Allo-HSCTAlive 91 mo28Feng et al. \[[@CR39]\]57IsolatedNoneNoneNASG → RefusedANEL 6 mo29Liu et al. \[[@CR40]\]50Not statedPelvic LANot statedNASGNot stated30Wang et al. \[[@CR41]\]28InitialNoneAfter 5 mo of MSM2aCTCR, died 20 moUterine body31Wang et al. \[[@CR42]\]38IsolatedNoneNoneNASGNot stated32Zhao et al. \[[@CR43]\]33IsolatedNoneNoneNACT (DNR + ARA-C)Alive33Hou et al. \[[@CR44]\]44IsolatedNoneNoneNANot statedNot statedOvary34Zhang et al. \[[@CR45]\]27InitialNoneSimultaneouslyM2CT (DNR + ARA-C)PR, MS resolved35Zheng et al. \[[@CR46]\]26IsolatedNoneNoneNASG → CT (DNR + ARA-C) → Auto-HSCTANEL 1 y after HSCT36Yu et al. \[[@CR47]\]35IsolatedNoneNoneNASG → CTANEL 3 y 9 mo37Yu et al. \[[@CR47]\]26Relapse (AML)NoneNoneNASGNot stated38Yu et al. \[[@CR47]\]24IsolatedNoneNoneNASG → CTANEL 5 mo39Zhou et al. \[[@CR48]\]27InitialNoneAfter 2 mo of MSM2SG → CT (DNR + ARA-C)Not stated40Zhou et al. \[[@CR49]\]36IsolatedNoneNoneNASG → CT (DNR + ARA-C)Not stated41Zhu et al. \[[@CR37]\]23IsolatedNoneNoneNACT (ARA-C)PR42Zhou et al. \[[@CR50]\]27Not statedNot statedNot statedNASGNot stated43Pang et al. \[[@CR51]\]23IsolatedNoneNoneNACT → RTDied 39 mo44Pang et al. \[[@CR51]\]22Relapse (AML-M3)NoneNot statedNACTDied 38 mo45Zhou et al. \[[@CR48]\]36Not statedLung, small intestine, brainNoneNACT (VP-16 + ARA-C)Died 1 mo (cerebral hemorrhage)46Wang et al. \[[@CR41]\]26SecondarySmall intestineNoneNASG → CTMS resolved, ANEL 15 moMultifocal47Zhang et al. \[[@CR52]\]29Initial (vulva, ovary)Whole bodyNot statedNARefusedDied 1 mo48Cheng et al. \[[@CR53]\]37Initial (uterine cervix, ovary)Right common iliac lymph nodesAfter 6 mo of MSNot statedSG → CT (DNR + ARA-C, DNR + ARA-C+ Vm-26) → nasopharyngeal TCL → AML → CT (CTX + ADM + VCR + PED+Vm-26)Metastasis to chest wall and anterior mediastinum49Qu et al. \[[@CR54]\]44Relapse (AML-M2a) (uterine body, cervix)NoneNoneNASG → CTANEL 1 y50Li et al. \[[@CR55]\]43uterine body, cervix, vaginaIliac perivascular LAPNoneNACT (PTX + PDD) → RT + CT (DNR + ARA-C)MS resolved, ANEL 6 mo after cessation of CT51Wu et al. \[[@CR56]\]25Uterine cervix, vaginaNoneNoneNACT (IDA + ARA-C)CR, ANEL 3 mo52Wang et al. \[[@CR57]\]43Uterine cervix, vaginaNoneNoneNACT (DNR + ARA-C, ARA-C, FA + ARA-C+ G-CSF), II (MTX + ARA-C + DXM)Cervical MS resolved, ANEL 7 mo53Long et al. \[[@CR58]\]46Relapse (AML-M2) (ovary, uterine cervix)None1 mo after SGM2SG → CT (MTX + VP16 + ARA-C)ANEL 8 mo54Huang et al. \[[@CR59]\]43Uterine cervix, left appendageNoneNoneNACTDied 11 mo55Xu et al. \[[@CR60]\]51Ovary, uterusColon, rectumNot statedNASG, refusedNot stated*ADM* Adriamycin, *AML* acute myeloid leukemia, *ANEL* alive with no evidence of leukemia, *ARA-C* cytarabine, *CR* complete remission, *CT* chemotherapy, *CTX* Cyclophosphamide, *d* day, *DNR* daunorubicin, *FA* Fludarabine, *HHT* homoharringtonine, *HSCT* hematopoietic stem cell transplantation, *Allo-HSCT* allogeneic HSCT, *Auto-HSCT* autologous HSCT, *IDA* idarubicin, *II* intrathecal injection, *LA* lymphadenopathy, *MIT* Mitoxantrone, *MDS* myelodysplastic syndrome, *mo* month, *NA* not applicable, *PED* Prednisone, *PDD* cisplatin, *PR* partial remission, *PTX* paclitaxel, *RT* radiotherapy, *SCC* squamous cell carcinoma, *SG* surgery, *TCL* T cell lymphoma, *VCR* Vincristine, *VP-16* Etoposide, *y* year

Being a rare entity, isolated MS often poses diagnostic challenge, and immunohistochemical examination is of great importance in the correct diagnosis. As the myeloblasts in MS have an antigen profile resembling that of the blasts and precursor cells in AML, the positivity of myeloperoxidase, CD43, CD68, CD117 and lysozyme help to recognize MS. The most important differential diagnoses include non-Hodgkin lymphoma of the lymphoblastic type, Burkitt's lymphoma, large-cell lymphoma and small round cell tumors \[[@CR61]\]. However, we did not detect any exclusive surface marker of MS involving gynecological tissue.

Our reviewed cohort showed that gynecological MS involved uterine cervix (40%), ovary (23.6%), vulva (10.9%), uterine body (5.5%) and vagina (3.6%) in a most-preferred-to-least-preferred order with around one sixth of cases had multifocal lesions, which differed from previous notion that the most frequently involved genital organ is the ovary followed by the cervix and uterus \[[@CR10], [@CR15], [@CR62]\]. The inconsistency might partly result from ethnic diversity. A 'skip' phenomenon was also noticed in nearly half of the multifocal MS patients that the myeloid blasts occurred at non-adjacent sites, which is uncommon in other gynecological malignancy.

The age of female-genital MS onset ranged from 22 to 78 years with an average age being 39.2 ± 1.7 years (Table [2](#Tab2){ref-type="table"}), which differed from a predilection of general MS for children \[[@CR63]\]. Particularly, MS arising at the ovaries mostly occurred in young adults, which was much earlier than the other single locations (27.5 ± 1.4 vs 43.5 ± 2.3, *P* = 0.0001). Female-genital MS could be asymptomatic (6 cases) or initially presented as mass formation (9 cases), abdominal pain (8 cases), ulceration (1 case), paramenia and vaginal bleeding (25 cases), which was similar to an earlier observation \[[@CR64]\]. Remarkably, the onset symptom of all the previously-reported vulvar MS was regional mass with our case distinctively being ulceration. Table 2Onset age and correlation with AML of reviewed myeloid sarcoma patientsMS siteOnset Age (year)Without AMLPreceding AMLCoinciding with AMLAML RelapseVulva25--78 (49.5 ± 9.3)1 (16.7%)1 (16.7%)4 (66.7%)─Vagina55--61 (58 ± 3)1 (100%)───Uterine cervix23--63 (41.3 ± 2.2)10 (58.8%)4 (23.5%)2 (11.8%)1 (5.9%)Uterine body33--44 (38.3 ± 3.2)3 (100%)───Ovary22--36 (27.5 ± 1.4)8 (66.7%)1 (8.3%)1 (8.3%)2 (16.7%)Multifocal25--51 (40.1 ± 2.8)5 (62.5%)1 (12.5%)─2 (25%)Total22--78 (39.2 ± 1.7)28 (59.6%)7 (14.9%)7 (14.9%)5 (10.6%)*AML* acute myeloid leukemia

Three fifths of MS patients are not correlated with AML or other hematopoietic disorders, with equally 14.9% cases preceding or coinciding with AML and 10.6% occurring as the first sign of AML relapse (Table [2](#Tab2){ref-type="table"}). While the few cases of vagina and uterine-body MS revealed no linkage with AML, vulvar MS exhibited a notably high rate of concurrent AML and secondary myeloid leukemia in a short time. The interval between the initial diagnosis of MS and systemic disease with medullary involvement ranged from 0.6 to 18 months with a mean value of 5.5 month, in accordance with the formerly-reported 5 to 11 months \[[@CR65]--[@CR67]\]. And, MS heralded AML relapse with or without marrow involvement, and the duration was from 6 to 67 months with a mean value of 33.6 months.

As evidenced from prior observation, FAB subtype M4 and M5 are mostly associated with extra medullary tissue involvement \[[@CR16]\]. Unexpectedly, our reviewed cohort displayed a predominance of M2 subtype (10 cases) with the remaining being M5 (2 cases) and M3 (1 case), suggesting that M2 subtype of AML was most inclined to develop MS in the Chinese population. The chromosomal abnormalities of MS include trisomy 4, trisomy 8, trisomy 11, monosomy 7, 16(q)-, 5q- and 20q-, while t (8;21)(q22;q22) and inv \[[@CR16]\] (p13;q22) were the most common chromosome rearrangements detected in AML-correlated MS \[[@CR12], [@CR68]\]. In our reviewed cases, three occurred t (8;21)(q22;q22), in conformity with the high incidence of t (8;21) in AML-M2 patients with MS \[[@CR68]\]. And, one AML-M5 patient had complex chromosomal aberrations of t (1;7)(p22;q36), t (3;21)(q22;q26) and loss of chromosome 16 \[[@CR20]\]. Recurrent AML1/ETO fusion genes were identified in two gynecological MS patients, whereas no cytogenetic defect was discovered in five patients.

Despite the local distribution of MS, chemotherapy was more effective than radiation therapy or surgical removal for improving disease-free intervals or survival \[[@CR69], [@CR70]\]. Additionally, allogeneic or autologous BM transplantation appeared to increase the odds of prolonged survival \[[@CR12]\]. The therapeutic measures taken by the reviewed MS patients were comprised of chemotherapy (16 cases), surgery (3 cases), radiotherapy (1 case) and chemotherapy-combined treatment (19 cases), the majority of which being chemotherapy plus surgery. The chemotherapy regimen, which proved to be helpful even after tumor recurrence, primarily relied on cytarabine (Table [1](#Tab1){ref-type="table"}). Recently, hypomethylating agents including decitabine and 5-azacitdine was considered as another option in the elderly patients \[[@CR71]\]. The longest disease-free survival of 91 months (case 27) was achieved in an isolated cervical MS case treated with chemotherapy, surgery and radiotherapy followed by the consolidation of allogeneic HSCT. However, we also noted that surgical removal of isolated cervical MS within 1 month of its onset (case 20, 28) was also successful. In brief, chemotherapy and allogeneic HSCT encompasses an optimal management of MS, and surgery and radiotherapy were ancillary modalities for initial debulking and rapid remission.

Previous evidence suggested that MS generally carries a rather poor prognosis with a 5-year survival rate being about 20%, which were not affected by patient age, gender, MS anatomic site, de novo presentation, history related to AML, histotype, phenotype nor cytogenetic findings \[[@CR12], [@CR72]\]. Moreover, the median survival for MS patients with or without AML has been reported to be 6 to 14 months and 36 months, respectively \[[@CR66]\]. For the entire reviewed group, the follow-up periods for 18 patients were 3 to 91 months with a mean duration of 18.3 months, whereas 12 patients died of the disease in an average of 13 months (0.9 to 39 months). We further analyzed the survival duration of these gynecological MS patients according to the tumor sites and BM involvement. Vulvar and multifocal MS seemed to have a poorer prognosis, while the medullary involvement might not further worsen their prognosis. Although t (8;21) represents a favorable prognostic factor in traditional AML, it did not indicate a better prognosis in MS \[[@CR12]\]. The one AML-M2 patient (case 30) with t (8;21)(q22;q22) received chemotherapy and died 20 months after the diagnosis.

In summary, we herein reported a rare case of vulvar MS and reviewed Chinese MS cases specially involving gynecological system. We discovered that MS most frequently involved uterine cervix followed by the ovary and vulva, and ovarian MS onset much earlier than other sites. Moreover, vulvar MS exhibited a notably high rate of concurrent AML and secondary myeloid leukemia in a short time, which require immediate management. Despite its limited distribution, MS should be tackled aggressively with chemotherapy followed by allogeneic HSCT if the appropriate donor is available. Female genital MS, especially vulvar MS, should be included in the differential diagnosis of gynecological neoplasm, which will facilitate its early diagnosis and prompt management.
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